Mylan at last acquires Meda, paying $9.9bn
Almost two years after launching two separate (but unsuccessful) hostile bids, Mylan NV is taking over publicly traded Swedish spec pharma Meda AB for SEK83.6bn ($9.9bn). Mylan will pay $8.5bn in cash (SEK165 ($19.68) per share, an 84% premium) and debt, and issue about $1.4bn in Mylan stock). The deal is subject to 90% of Meda shareholders tendering their shares; stakeholders accounting for about 30% of shares have already accepted the offer.
- Generic Drugs
- OTC, Consumer
- Specialty Pharmaceuticals
- Full Acquisition
- Payment Includes Cash
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.